title: Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle.
abstract: OBJECTIVE
  Cytokines are elevated in various insulin-resistant states, including type 2 diabetes and obesity, although the contribution of interleukin-6 (IL-6) in the induction of these diseases is controversial.
  
  
  METHODS
  We analyzed the impact of IL-6 on insulin action in murine primary myocytes, skeletal muscle cell lines, and mice (wild type and protein-tyrosine phosphatase 1B [PTP1B] deficient).
  
  
  RESULTS
  IL-6 per se increased glucose uptake by activating serine/threonine protein kinase 11 (LKB1)/AMP-activated protein kinase/protein kinase B substrate of 160 kDa (AS160) pathway. A dual effect on insulin action was observed when myotubes and mice were exposed to this cytokine: additive with short-term insulin (increased glucose uptake and systemic insulin sensitivity) but chronic exposure produced insulin resistance (impaired GLUT4 translocation to plasma membrane and defects in insulin signaling at the insulin receptor substrate 1 [IRS-1] level). Three mechanisms seem to operate in IL-6-induced insulin resistance: activation of c-Jun NH(2)-terminal kinase 1/2 (JNK1/2), accumulation of suppressor of cytokine signaling 3 (socs3) mRNA, and an increase in PTP1B activity. Accordingly, silencing JNK1/2 with either small interfering RNA or chemical inhibitors impaired phosphorylation of IRS-1 (Ser307), restored insulin signaling, and normalized insulin-induced glucose uptake in myotubes. When using a pharmacological approach, liver X receptor agonists overcome IL-6-induced insulin resistance by producing downregulation of socs3 and ptp1b gene expression. Finally, the lack of PTP1B confers protection against IL-6-induced insulin resistance in skeletal muscle in vitro and in vivo, in agreement with the protection against the IL-6 hyperglycemic effect observed on glucose and insulin tolerance tests in adult male mice.
  
  
  CONCLUSIONS
  These findings indicate the important role of IL-6 in the pathogenesis of insulin resistance and further implicate PTP1B as a potential therapeutic target in the treatment of type 2 diabetes.
authors.affiliation: Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Complutense University, Madrid, Spain.
authors.forename: Iria
authors.initials: I
authors.lastname: Nieto-Vazquez
authors.forename: Sonia
authors.initials: S
authors.lastname: Fernández-Veledo
authors.forename: Cristina
authors.initials: C
authors.lastname: de Alvaro
authors.forename: Margarita
authors.initials: M
authors.lastname: Lorenzo
mesh_terms: D000263:Adenylate Kinase / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D001692:Biological Transport / Q000187:drug effects; D005121:Extremities; D005947:Glucose / Q000378:metabolism; D051275:Glucose Transporter Type 4 / Q000187:drug effects / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology*; D015850:Interleukin-6 / Q000502:physiology*; D051379:Mice; D032342:Muscle Cells / Q000187:drug effects / Q000502:physiology*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000502:physiology*; D032446:Myoblasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D016133:Polymerase Chain Reaction; D021381:Protein Transport / Q000187:drug effects / Q000502:physiology; D051057:Proto-Oncogene Proteins c-akt / Q000187:drug effects / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics
chemical_list: D051275:Glucose Transporter Type 4; D007328:Insulin; D015850:Interleukin-6; D034741:RNA, Small Interfering; C495693:Slc2a4 protein, mouse; D051057:Proto-Oncogene Proteins c-akt; D000263:Adenylate Kinase; D005947:Glucose
references.citation: Diabetologia. 2004 Nov;47(11):1879-87
references.pmid: 15551046
references.citation: J Biol Chem. 2003 Nov 14;278(46):45777-84
references.pmid: 12952969
references.citation: Diabetologia. 2005 Jul;48(7):1386-92
references.pmid: 15959754
references.citation: J Clin Endocrinol Metab. 2001 Dec;86(12):5973-80
references.pmid: 11739472
references.citation: Mol Cell Biol. 2000 Aug;20(15):5479-89
references.pmid: 10891488
references.citation: Diabetologia. 2006 Dec;49(12):3038-48
references.pmid: 17072583
references.citation: Br J Pharmacol. 2005 Sep;146(2):234-43
references.pmid: 15997237
references.citation: EMBO J. 2005 May 18;24(10):1810-20
references.pmid: 15889149
references.citation: J Biol Chem. 2004 Jun 4;279(23):24844-51
references.pmid: 15031294
references.citation: J Clin Invest. 1995 May;95(5):2409-15
references.pmid: 7738205
references.citation: J Biol Chem. 2007 Aug 17;282(33):23829-40
references.pmid: 17545163
references.citation: Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1272-8
references.pmid: 12388119
references.citation: Diabetes. 2004 Jul;53(7):1643-8
references.pmid: 15220185
references.citation: Biochem J. 2007 May 1;403(3):473-81
references.pmid: 17253964
references.citation: Diabetes. 2004 Sep;53(9):2232-41
references.pmid: 15331532
references.citation: Diabetes. 2000 Mar;49(3):517-20
references.pmid: 10868978
references.citation: Endocrinology. 2006 Jan;147(1):552-61
references.pmid: 16223857
references.citation: J Biol Chem. 2003 Mar 21;278(12):10443-9
references.pmid: 12531895
references.citation: Diabetes. 2006 Dec;55 Suppl 2:S48-54
references.pmid: 17130644
references.citation: Mol Cell Biol. 2004 Jun;24(12):5434-46
references.pmid: 15169905
references.citation: J Biol Chem. 2006 Sep 15;281(37):26865-75
references.pmid: 16798732
references.citation: Diabetes. 2002 Dec;51(12):3391-9
references.pmid: 12453891
references.citation: Diabetes. 2006 Oct;55(10):2688-97
references.pmid: 17003332
references.citation: Diabetes. 2007 Jun;56(6):1630-7
references.pmid: 17363741
references.citation: Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E867-77
references.pmid: 16822958
references.citation: Am J Physiol Endocrinol Metab. 2001 May;280(5):E745-51
references.pmid: 11287357
references.citation: Diabetologia. 2008 Jul;51(7):1306-16
references.pmid: 18437347
references.citation: Am J Physiol Endocrinol Metab. 2002 Sep;283(3):E514-24
references.pmid: 12169445
references.citation: Diabetes. 2004 Apr;53(4):1060-7
references.pmid: 15047622
references.citation: Biochem Biophys Res Commun. 2003 Nov 14;311(2):372-9
references.pmid: 14592424
references.citation: Annu Rev Biochem. 2006;75:137-63
references.pmid: 16756488
references.citation: J Clin Invest. 2001 Jan;107(2):181-9
references.pmid: 11160134
references.citation: Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E310-7
references.pmid: 15068958
references.citation: Mol Cell Biol. 2007 Nov;27(21):7727-34
references.pmid: 17724080
references.citation: J Biol Chem. 2008 May 23;283(21):14230-41
references.pmid: 18281274
references.citation: Diabetes. 2007 Feb;56(2):404-13
references.pmid: 17259385
references.citation: Cell Metab. 2007 Apr;5(4):237-52
references.pmid: 17403369
references.citation: J Clin Invest. 1996 Mar 15;97(6):1471-7
references.pmid: 8617880
references.citation: Diabetologia. 2006 May;49(5):990-9
references.pmid: 16482468
references.citation: Diabetes. 2005 Dec;54 Suppl 2:S114-24
references.pmid: 16306329
references.citation: Endocr Rev. 2006 May;27(3):318-29
references.pmid: 16556851
references.citation: J Clin Invest. 1997 Jul 15;100(2):449-58
references.pmid: 9218523
references.citation: J Biol Chem. 2007 Mar 16;282(11):7991-6
references.pmid: 17244624
references.citation: J Clin Endocrinol Metab. 2002 May;87(5):2084-9
references.pmid: 11994345
references.citation: FASEB J. 2003 Nov;17(14):2166-8
references.pmid: 12958150
references.citation: J Immunol. 2005 Mar 1;174(5):2494-8
references.pmid: 15728454
references.citation: Mol Endocrinol. 2006 Dec;20(12):3364-75
references.pmid: 16945991
references.citation: Diabetes. 2006 Jul;55(7):2067-76
references.pmid: 16804077
references.citation: Nat Med. 2002 Jan;8(1):75-9
references.pmid: 11786910
references.citation: J Biol Chem. 2004 Apr 23;279(17):17070-8
references.pmid: 14764603